- Home
- GYRE vs NBXG Comparison
GYRE vs NBXG Comparison
Compare GYRE & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NBXG
- Stock Information
- Founded
- GYRE 2002
- NBXG 2021
- Country
- GYRE United States
- NBXG United States
- Employees
- GYRE N/A
- NBXG N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NBXG Trusts Except Educational Religious and Charitable
- Sector
- GYRE Health Care
- NBXG Finance
- Exchange
- GYRE Nasdaq
- NBXG Nasdaq
- Market Cap
- GYRE 1.3B
- NBXG 1.0B
- IPO Year
- GYRE N/A
- NBXG N/A
- Fundamental
- Price
- GYRE $13.12
- NBXG $12.89
- Analyst Decision
- GYRE
- NBXG
- Analyst Count
- GYRE 0
- NBXG 0
- Target Price
- GYRE N/A
- NBXG N/A
- AVG Volume (30 Days)
- GYRE 53.3K
- NBXG 243.7K
- Earning Date
- GYRE 11-13-2024
- NBXG 01-01-0001
- Dividend Yield
- GYRE N/A
- NBXG 10.25%
- EPS Growth
- GYRE N/A
- NBXG N/A
- EPS
- GYRE N/A
- NBXG N/A
- Revenue
- GYRE $105,033,000.00
- NBXG N/A
- Revenue This Year
- GYRE $25.32
- NBXG N/A
- Revenue Next Year
- GYRE $12.95
- NBXG N/A
- P/E Ratio
- GYRE N/A
- NBXG N/A
- Revenue Growth
- GYRE N/A
- NBXG N/A
- 52 Week Low
- GYRE $8.26
- NBXG $9.31
- 52 Week High
- GYRE $30.40
- NBXG $12.23
- Technical
- Relative Strength Index (RSI)
- GYRE 41.11
- NBXG 48.20
- Support Level
- GYRE $13.07
- NBXG $12.48
- Resistance Level
- GYRE $19.00
- NBXG $13.39
- Average True Range (ATR)
- GYRE 1.16
- NBXG 0.20
- MACD
- GYRE -0.21
- NBXG 0.00
- Stochastic Oscillator
- GYRE 7.39
- NBXG 45.05
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income.